Neutralizing antibody targeting sEV-S100A10 was able to sensitize HCC cells to sorafenib treatment, and combination treatment synergistically reduced tumor growth in subcutaneous xenograft model. The gene discussed is S100A10; the disease is hepatocellular carcinoma.